Robert S. Goodenow, based in Coto de Casa, California, is a notable inventor who has contributed significantly to the field of immunology. He holds four patents, showcasing his innovative approach to regulating surface membrane receptor responses, particularly concerning MHC Class I antigens.

Latest Patents

Goodenow's latest patents involve methods and compositions for modulating the interaction between MHC Class I antigens and surface membrane receptors. His first patent describes various techniques that can enhance or reduce this interaction, such as increasing the surface expression of MHC Class I antigens or employing agents that influence these interactions. He also explores the use of oligopeptides to act as agents that impact the interaction, which can be employed in screening assays for drug development aimed at affecting surface receptor activity. These innovative methods open up new possibilities for therapeutic interventions and drug discovery related to immune responses.

Career Highlights

Robert S. Goodenow is affiliated with the University of California, where his research focuses on advancing our understanding of immune system modulation. His work is vital in developing therapeutic strategies aimed at improving clinical outcomes for conditions influenced by immune responses.

Collaborations

Throughout his career, Goodenow has collaborated with esteemed colleagues, including Lennart Olsson and Avram Goldstein. These partnerships enhance the scope and depth of his research, allowing for a more robust approach to the challenges in immunology.

Conclusion

In summary, Robert S. Goodenow's innovative contributions to the modulation of MHC Class I antigens demonstrate the significant impact of his work in the field of immunology. With his patents and collaboration with other experts, he plays a crucial role in paving the way for advancements that could lead to new therapeutic solutions in the medical field.